Nitrogen Containing Patents (Class 514/459)
  • METHODS FOR THE TREATMENT OF VIRAL CONDITIONS
    Publication number: 20110183892
    Abstract: The invention is directed to a method of stimulating PRF in a viral cell by administering an aminoglycoside antibiotic to said cell. In another embodiment, the invention is directed to a method of inhibiting viral replication by administering an aminoglycoside antibiotic to a viral cell. The invention is also directed to method of treating a viral infection in a patient suffering therefrom comprising administering to said patient an aminoglycoside antibiotic.
    Type: Application
    Filed: April 9, 2010
    Publication date: July 28, 2011
    Inventors: Jonathan D. Dinman, Jeffrey J. DeStefano
  • Compositions and kits for treating influenza
    Patent number: 7981930
    Abstract: Kits comprising an M2 inhibitor selected from amantadine and rimantadine; ribavirin, and a neuraminidase inhibitor (NAi) in an amount that is antivirally effective in the combination, an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin and a neuraminidase inhibitor are provided for the treatment of influenza. Some embodiments of the kits comprise an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin, and a neuraminidase inhibitor.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: July 19, 2011
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Jack Nguyen, Gregory T. Went, Paul Spence, Timothy J. Fultz, David Chernoff, Terry L. Burkoth, Rowan Chapman, Mickey S. Urdea
  • Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof
    Publication number: 20110172297
    Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of Formula (I): as defined in the specification. The invention is also directed to compositions containing the compounds of Formula (I) as AMPA modulators.
    Type: Application
    Filed: September 18, 2009
    Publication date: July 14, 2011
    Inventors: Kimberly Gail Estep, Antone F.J. Fliri, Randall James Gallaschun, Christopher John O'Donnell, Nandini Chaturbhai Patel, Jacob Bradley Schwarz, Longfei Xie
  • Method for angiogenesis inhibition or immunostimulation
    Patent number: 7977379
    Abstract: The present invention relates to a composition for use in prevention or treatment of a vascular-related disease, particularly used for angiogenesis inhibition, tumor growth inhibition or tumor metastasis inhibition, or immunostimulation, which comprises glutamic acid or derivatives thereof, preferably glutamic acid is anhydrous glutamic acid represented by Formula (1) or pyroglutamic acid, and a pharmaceutically acceptable carrier or an edible carrier, and a method of preventing or treating a vascular-related disease.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: July 12, 2011
    Assignee: BHN Co., Ltd.
    Inventors: Takashi Kouge, Akihiro Yamashita, Keno Ishihara
  • Prodrugs of Neuraminidase Inhibitors
    Publication number: 20110160127
    Abstract: A new class of neuramidase inhibitor prodrugs is provided characterized by a prodrug moiety of a carboxyl group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide or a carbonyl ethoxy tripeptide, a guanidine group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide, a carbonyl ethoxy tripeptide; a primary alcohol modified to form an esterified single amino acid, dipeptide or tripeptide of zanavimir of the unaltered therapeutic agent. Exemplary therapeutic agents so modified to form prodrugs include zanavimir, oseltamivir and peramivir. The prodrug has increased oral bioavailability relative to the unaltered neuraminidase inhibitor and is effective in the inhibition of viral infections involving neuraminidase in the viral reproductive cycle.
    Type: Application
    Filed: April 15, 2009
    Publication date: June 30, 2011
    Applicant: TSRL, Inc.
    Inventors: John Hilfinger, Gordon Amidon
  • Renin Inhibitors and Methods of Use Thereof
    Publication number: 20110160300
    Abstract: Disclosed are aspartic protease inhibitors represented by the following Formula: wherein R1, R2, R3, R4, R5, R6, R7a, R7b and n are as defined herein, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods for treating an aspartic protease mediated disorder using the same.
    Type: Application
    Filed: June 18, 2009
    Publication date: June 30, 2011
    Inventors: Marlys Hammond, Patrick Stoy
  • COMPOSITION AND METHOD FOR INHIBITING NOROVIRUS INFECTION
    Publication number: 20110152263
    Abstract: A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia. The composition contains a therapeutically effective amount of a binding-inhibiting compound selected from Compounds 1 through 15, and at least one diluent, carrier or excipient. The Compounds competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions can be administered to a human prior to or after infection by a Norovirus, to prevent or ameliorate an infection.
    Type: Application
    Filed: November 15, 2007
    Publication date: June 23, 2011
    Inventor: Xi JIANG
  • POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER
    Publication number: 20110142950
    Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Application
    Filed: October 29, 2010
    Publication date: June 16, 2011
    Applicant: INTEZYNE TECHNOLOGIES, INCORPORATED
    Inventors: Kevin N. Sill, Habib Skaff, Jonathan Rios-Doria
  • C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS
    Publication number: 20110143943
    Abstract: The present invention relates to novel C2-phenyl-substituted cyclic ketoenols of the formula (I) in which W, X, Y, Z and CKE are as defined in the description, to processes for their preparation and to their use as pesticides and herbicides.
    Type: Application
    Filed: February 17, 2011
    Publication date: June 16, 2011
    Applicant: Bayer Aktiengesellschaft
    Inventors: Michael RUTHER, Hermann Hagemann, Udo Schneider, Markus Dollinger, Peter Dahmen, Ulrike Wachendorff-Neumann, Reiner Fischer, Alan Graff, Thomas Bretschneider, Christoph Erdelen, Mark Wilhelm Drewes, Dieter Feucht, Folker Lieb
  • ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES
    Publication number: 20110144197
    Abstract: Compounds of the general formula (formula I) in which the meanings of the substituents R1 and R6 are as indicated in claim 1, have renin-inhibiting properties and can be used as medicines.
    Type: Application
    Filed: February 18, 2011
    Publication date: June 16, 2011
    Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Stefan Stutz, Aleksandar Stojanovic, Stjepan Jelakovic, Christiane Marti
  • Novel Uses of Neuraminidase Inhibitors in Infectious Diseasess
    Publication number: 20110144048
    Abstract: The present invention relates to methods of decreasing the infectivity, morbidity and rate of mortality, in treating diseases associated with a variety of pathogenic organisms, specifically diseases involving one or more pathogens that require neuraminidase as a virulence factor. In addition, the present invention uses biology based therapy to treat neuraminidase dependent infections or diseases dependent on sialic acid metabolism.
    Type: Application
    Filed: February 9, 2011
    Publication date: June 16, 2011
    Inventor: Jack J. Broadhurst, III
  • Methods and Compositions to Determine the Chemosensitizing Dose of Suramin Used in Combination Therapy
    Publication number: 20110142794
    Abstract: A method for determining a therapeutically effective amount of suramin for administering to a patient, who is to receive a cytotoxic agent, which comprises the steps of determining the circulating suramin concentration in the patient; administering suramin, if required, to establish a low circulating concentration of suramin in the patient of below about 200 ?M; and administering the chemotherapeutic agent to the patient when the low circulating concentration of suramin is present in the patient. Conveniently a nomogram can be constructed for use in clinical settings with the suramin.
    Type: Application
    Filed: February 21, 2011
    Publication date: June 16, 2011
    Inventors: Jessie L.-S. Au, M. Guillaume Wientjes
  • SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS
    Publication number: 20110112076
    Abstract: The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).
    Type: Application
    Filed: July 13, 2009
    Publication date: May 12, 2011
    Inventors: Leslie Wighton McQuire, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi, Sven Weiler
  • INSECTICIDAL FERMENTATION BROTH FROM ACTINOMYCETES
    Publication number: 20110112185
    Abstract: Methods and compositions are provided for the preparation of insecticidal compositions.
    Type: Application
    Filed: November 4, 2010
    Publication date: May 12, 2011
    Applicant: AgraQuest, Inc.
    Inventors: Hong Zhu, Jorge Jimenez, Colleen Taylor, Magalie Guilhabert-Goya, Jonathan Margolis
  • Oncotherapeutic Application of Inhibitors of High-Affinity Glucose Transporters
    Publication number: 20110104249
    Abstract: The subject invention concerns materials and methods for treating oncological disorders in a person or animal using any agent or compound that inhibits uptake of glucose into a cell. The subject invention also concerns methods for inducing apoptosis and inhibiting the proliferation or survival of a cell. In one embodiment, the methods comprise administering an effective amount of an agent or compound that inhibits the activity of one or more glucose transporter proteins, such as Glut-1. An antibody that binds to and inhibits a glucose transporter protein can be used in the present methods.
    Type: Application
    Filed: August 15, 2008
    Publication date: May 5, 2011
    Applicant: University of South Florida
    Inventor: George R. Simon
  • PARTICULATE DRUG CARRIERS AS DESENSITIZING AGENTS
    Publication number: 20110097387
    Abstract: The present invention provides methods for desensitization for prevention or diminishing hypersensitivity reactions including C activation-related pseudoallergy (CARPA) and other reactions to particulate medicines. The desensitization is performed via pretreatment using a drug-free vehicle or carrier to eliminate or diminish the clinical symptoms of hypersensitivity.
    Type: Application
    Filed: December 7, 2008
    Publication date: April 28, 2011
    Inventors: Yechezkel Barenholz, Janos Szebeni, Miklos Toth, Laszlo Rosivall
  • COMPOSITIONS COMPRISING POLYMERIC MICELLES FOR DRUG DELIVERY
    Publication number: 20110091534
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
    Type: Application
    Filed: December 7, 2010
    Publication date: April 21, 2011
    Applicant: Intezyne Technologies, Inc.
    Inventors: Kurt Breitenkamp, Kevin N. Sill, Habib Skaff, Rebecca Breitenkamp
  • CYCLIC AMINO ACIDS FOR THE TREATMENT OF PAIN
    Publication number: 20110092564
    Abstract: Compositions comprising cyclic amino acids or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. Said composition are for use in the treatment of pain. Pain includes both acute and chronic forms of pain. The preferred cyclic amino acid is 1-aminocyclobutane-1-carboxylic acid (ACBC).
    Type: Application
    Filed: February 26, 2009
    Publication date: April 21, 2011
    Inventors: Ernest Puil, Bernard A. Macleod, Richard Wall
  • Compounds which modulate the CB2 receptor
    Patent number: 7928123
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: April 19, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Angela Berry, Pier Francesco Cirillo, Doris Riether, David Thomson, Renee M. Zindell, Nigel Blumire, Chandana Chowdhury, Monika Ermann, James Edward Jenkins, Innocent Mushi, Christopher Francis Palmer, Malcolm Taylor
  • SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY
    Publication number: 20110086909
    Abstract: The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.
    Type: Application
    Filed: September 15, 2010
    Publication date: April 14, 2011
    Inventors: Kazunori KOIDE, Brian J. Albert, Ananthapadmanabhan Sivaramakrishnan
  • NOVEL 17 BETA LUPANE DERIVATIVES
    Publication number: 20110077251
    Abstract: The invention relates to 17? lupane derivatives of formula (I): wherein R1 and X are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infection by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.
    Type: Application
    Filed: August 16, 2010
    Publication date: March 31, 2011
    Inventors: Christophe Moinet, Bingcan Liu, Liliane Halab, Nathalie Turcotte, Real Denis, Carl Poisson, Paul Nguyen-Ba, Monica Bubenik, Laval Chan Chun Kong
  • CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS
    Publication number: 20110053904
    Abstract: The present invention relates to the use of a compound of formula I wherein R1, R2, R3, R4, X and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.
    Type: Application
    Filed: August 19, 2010
    Publication date: March 3, 2011
    Inventors: Sabine Kolczewski, Emmanuel Pinard
  • N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE
    Publication number: 20110039853
    Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
    Type: Application
    Filed: February 19, 2008
    Publication date: February 17, 2011
    Inventor: Soren Ebdrup
  • Compositions, Methods, and Kits for Treating Influenza Viral Infections
    Publication number: 20110028510
    Abstract: The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).
    Type: Application
    Filed: February 18, 2010
    Publication date: February 3, 2011
    Applicants: COMBINATORX (SINGAPORE) PTE. LTD., EXCRX (Singapore) PTE. LTD. (F.K.A. CombinatoRx (Singapore) PTE. LTD.
    Inventors: Ralf Altmeyer, Geeta Sharma, Danilal Champalal Sharma, Vishal Vikas Pendharkar
  • Method Of Treating Malignant Solid Tumors Using Transcatheter Arterial Chemoembolization (TACE)
    Publication number: 20110020427
    Abstract: This invention is directed to methods of treating solid tumor cancers, particularly refractory cancers by administration of two pluralities of microparticles, one comprising drug-carrying microparticles sized to lodge at the tumor preferably in the capillary bed of the tumor and the other comprising non-drug-carrying microparticles sized to lodge in the arterial system servicing the tumor so as to embolize the tumor.
    Type: Application
    Filed: July 24, 2009
    Publication date: January 27, 2011
    Applicant: Abbott Cardiovascular Systems Inc.
    Inventors: Liangxuan Zhang, Florencia Lim
  • Cancer Chemoprevention Strategy Based on Loss of Imprinting of IGF2
    Publication number: 20110014204
    Abstract: The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying increased risk in developing CRC in a subject, including methods of assessing the efficacy of a chemotherapeutic regimen. Further, the present invention relates to methods for identifying anti-neoplastic agents.
    Type: Application
    Filed: December 7, 2007
    Publication date: January 20, 2011
    Inventors: Andrew P. Feinberg, Andre Levchenko, Dan L. Longo, Minoru S.H. Ko
  • Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
    Patent number: 7868041
    Abstract: The present invention provides cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, methods of making cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs. The present invention also provides methods of using cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: January 11, 2011
    Assignee: XenoPort, Inc.
    Inventors: Mark A. Gallop, Jia-Ning Xiang, Fenmei Yao, Laxminarayan Bhat
  • N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE
    Publication number: 20110003852
    Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
    Type: Application
    Filed: February 18, 2008
    Publication date: January 6, 2011
    Inventor: Soren Ebdrup
  • Compositions and kits for treating influenza
    Patent number: 7858660
    Abstract: Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: December 28, 2010
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Jack Nguyen, Gregory T. Went, Paul Spence, Timothy J. Fultz, David Chernoff, Terry L. Burkoth, Rowan Chapman, Mickey S. Urdea
  • CANCER SENSITIZER COMPRISING CHLOROGENIC ACID
    Publication number: 20100323033
    Abstract: The present invention relates to a cancer sensitizer comprising chlorogenic acid or a derivative thereof. In particular, the present invention relates to a cancer sensitizer comprising chlorogenic acid or a derivative thereof, which can make cancer cells sensitive to anticancer agents to increase the therapeutic effect of anticancer agents. In addition, the present invention relates to a composition for inhibiting the chemo-resistance of cancer cells, comprising chlorogenic acid or a derivative thereof in combination with a pharmaceutically acceptable carrier, an anticancer composition comprising an anticancer agent in addition to the composition, and a method for disrupting the chemo-resistance of cancer cells, comprising administration of the cancer sensitizer.
    Type: Application
    Filed: October 1, 2008
    Publication date: December 23, 2010
    Inventors: Soo Youl Kim, Kang-Seo Park, Kyung chae Jeong
  • COMPOUNDS WITH MDR1-INVERSE ACTIVITY
    Publication number: 20100316655
    Abstract: Disclosed herein are drug compounds that have MDR-inverse activity and thus are effective against multidrug-resistant cells. Exemplary compounds disclosed herein have the structure: Examples of the disclosed compounds have been found to have, inter alia, efficacy in directly treating multidrug resistant cells, rendering multidrug resistant cells susceptible to other chemotherapeutics and in some instances reversing multidrug resistance.
    Type: Application
    Filed: February 10, 2009
    Publication date: December 16, 2010
    Inventors: Matthew D. Hall, Michael M. Gottesman, Jennifer L. Hellawell, Joseph A. Ludwig, Henry M. Fales, Noeris K. Salam, Gergely Szakács
  • PHARMACEUTICALLY ACTIVE COMPOSITIONS COMPRISING OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES
    Publication number: 20100297262
    Abstract: Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of inflammation and cancer.
    Type: Application
    Filed: April 16, 2010
    Publication date: November 25, 2010
    Applicant: COLBY PHARMACEUTICAL COMPANY
    Inventors: Hirak S. Basu, David A. Zarling
  • METHOD FOR ADMINISTRATION OF PEGYLATED LIPOSOMAL DOXORUBICIN
    Publication number: 20100297216
    Abstract: An embodiment of the present invention comprises a method of treating malignancies in a subject in need of treatment comprising administering to the subject a high loading dose of a pegylated liposomal doxorubicin (PLD) in an initial cycle, followed by a reduced dose in a second cycle, wherein the second cycle reduced dose is in the range of 20% to 50%, preferably 50%, of the initial loading dose, and thereafter one or more maintenance doses in further cycles. The interval between dose cycles is in the range of about three-to-four weeks, preferably about four weeks. The initial loading dose is in the range of between the maximum tolerated dose (MTD) and the recommended dose, preferably the MTD (for instance, in the range of about 70 mg/m2 to 50 mg/m2, preferably 60 mg/m2). The one or more maintenance doses are in the range of about 40 mg/m2 to 50 mg/m2, preferably 45 mg/m2).
    Type: Application
    Filed: January 21, 2007
    Publication date: November 25, 2010
    Inventor: Alberto A. Gabizon
  • SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750
    Publication number: 20100286118
    Abstract: The present invention provides compounds of formula (I) in which y, m, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: May 6, 2010
    Publication date: November 11, 2010
    Inventors: Rhonan Ford, Andrew Mather, Antonio Mete, Ian Millichip
  • Carboxamide Derivatives As Therapeutic Agents
    Publication number: 20100286197
    Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
    Type: Application
    Filed: July 20, 2010
    Publication date: November 11, 2010
    Inventors: Adnan M.M. Mjalli, Rober C. Andrews, Ramosh Gopalaswamy, Chris Wysong
  • POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER
    Publication number: 20100278928
    Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Application
    Filed: April 30, 2010
    Publication date: November 4, 2010
    Applicant: Intezyne Technologies, Incorporated
    Inventors: Kevin N. Sill, Jonathan Rios-Doria, Habib Skaff, Gregoire Cardoen
  • PREDICTING RESPONSIVENESS TO CANCER THERAPEUTICS
    Publication number: 20100279957
    Abstract: Provided herein are methods for predicting the responsiveness of a cancer to a chemotherapeutic agent using gene expression profiles. In particular, methods for predicting the responsiveness to 5-fluorouracil, adriamycin, cytotoxan, docetaxol, etoposide, taxol, topotecan, PB kinase inhibitors and Src inhibitors are provided. Methods for developing treatment plans for individuals with cancer are also provided. Kits including gene chips and instructions for predicting responsiveness and computer readable media comprising responsivity information are also provided.
    Type: Application
    Filed: October 20, 2008
    Publication date: November 4, 2010
    Inventors: Anil Potti, Joseph R. Nevins, Johnathan M. Lancaster
  • TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZYLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISBUSTITUTED PYRAN DERIVATIVES
    Publication number: 20100280091
    Abstract: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.
    Type: Application
    Filed: July 15, 2010
    Publication date: November 4, 2010
    Applicant: WAYNE STATE UNIVERSITY
    Inventor: Aloke K. Dutta
  • Siglec inhibitors
    Patent number: 7820714
    Abstract: The invention relates to Siglec inhibitors that have an increased affinity for the receptor molecule. The Siglec inhibitors provided by the invention are preferably selective of a given Siglec molecule. The invention further relates to a method for producing Siglec inhibitors and to a method for increasing the binding selectivity for a given Siglec molecule. The invention also relates to pharmaceutical compositions that contain the Siglec inhibitors and to medical indications for the Siglec inhibitors.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: October 26, 2010
    Inventors: Sorge Kelm, Reinhard Brossmer
  • Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers
    Publication number: 20100260743
    Abstract: There are provided amphiphilic biodegradable copolymers comprising a hydrophilic backbone with pendant aliphatic groups as the hydrophobic component. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors that are capable of solubilizing insoluble organic compounds such as drugs, vitamins, dyes, and imaging agents. The polymers optionally feature reactive functional groups that provide attachment points for antibodies, ligands, and other targeting moieties useful for the targeted delivery of drugs and imaging agents.
    Type: Application
    Filed: January 19, 2006
    Publication date: October 14, 2010
    Applicant: ALLEXCEL, INC.
    Inventors: Anil Diwan, Ann Louise Onton, Jayant G. Tatake
  • Biologic Modulations with Nanoparticles
    Publication number: 20100247662
    Abstract: Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target. Compositions and methods of use arc also set forth.
    Type: Application
    Filed: January 11, 2007
    Publication date: September 30, 2010
    Inventor: Gretchen M. Unger
  • C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for the Treatment of Anxiety Disorders
    Publication number: 20100249225
    Abstract: Pharmaceutical formulations of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for treating anxiety, anxiety attacks and disorders as well as depression. Related methods of treating anxiety and anxiety attacks or depression are also provided, including methods of administering the active compounds as adjuvants to an antidepressant.
    Type: Application
    Filed: June 9, 2010
    Publication date: September 30, 2010
    Applicant: GRUENENTHAL GmbH
    Inventors: Petra Bloms-Funke, Werner Englberger, Hagen-Heinrich Hennies
  • Cycloalkylidene compounds as modulators of estrogen receptor
    Patent number: 7799828
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: September 21, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
  • Differential Drug Sensitivity
    Publication number: 20100233171
    Abstract: We describe a method to diagnose and treat an animal, preferably a human, suffering from a condition, typically cancer, that would benefit from a stimulation of apoptosis in tumour cells and including screening methods to identify new chemotherapeutic agents.
    Type: Application
    Filed: November 20, 2009
    Publication date: September 16, 2010
    Inventor: XIN LU
  • COATED TABLET
    Publication number: 20100233262
    Abstract: A main object of the present invention is to provide a novel coated tablet which contains a drug having a guanidino group and does not suffer an obvious color change even when packed in a one-dose pack together with a drug having a (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (DMDO) group. The present invention provides a coated tablet characterized in that an uncoated tablet containing a drug having a guanidino group has been coated with a polyvinyl alcohol for film coating which comprises polyvinyl alcohol, acrylic acid, and methyl methacrylate.
    Type: Application
    Filed: June 12, 2007
    Publication date: September 16, 2010
    Applicant: Nippon Shinyaku Co., Ltd.
    Inventors: Hironobu Kato, Hirokazu Sakamoto
  • Dimeric compounds and their use as anti-viral agents
    Patent number: 7795301
    Abstract: The invention relates to compounds of general formula (I); in which R is an amino or guanidino group; R2 is acetyl or trifluoroacetyl; and n is an integer from 10 to 18 or a pharmaceutically acceptable derivative thereof, methods for their preparation, pharmaceutical formulations containing them or their use in the prevention or treatment of a viral infection.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: September 14, 2010
    Assignee: Biota Scientific Management Pty, Ltd.
    Inventors: Derek A. Demaine, Graham G. A. Inglis, Simon J. F. MacDonald, Stephen E. Shanahan, Simon P. Tucker, Keith G. Watson, Wen-Yang Wu
  • N-(2-amino-phenyl)-amide derivatives
    Patent number: 7795315
    Abstract: The present invention provides novel compounds of the general formula (I) and pharmaceutically acceptable salts thereof, processes for the manufacture of these novel compounds and medicaments containing such compounds. The compounds of the present invention show anti-proliferative and differentiation-inducing activity, which results in inhibition of tumor cell proliferation, induction of apoptosis and inhibition of invasion. The invention also covers the use of such compounds for the treatment of diseases such as cancer and for the manufacture of corresponding medicaments.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: September 14, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Li Chen, Yun He, Jason Christopher Wong
  • METHOD FOR TREATING PAIN OR OPIOID DEPENDENCE USING A SPECIFIC TYPE OF NON-OPIOID AGENT IN COMBINATION WITH A SELECTIVE EXCITATORY-OPIOID-RECEPTOR INACTIVATOR
    Publication number: 20100203084
    Abstract: The present invention provides a method for treating pain in a subject in need of treatment, by administering to the subject a non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator, in amounts effective to treat pain in the subject. Also disclosed is a method for treating opioid-withdrawal effects in a subject in need of treatment, by the administration to the subject of a non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator, in amounts effective to treat opioid-withdrawal effects in the subject. Finally, the present invention provides a pharmaceutical composition comprising a non-opioid agent and a selective excitatory-opioid-receptor inactivator, and a pharmaceutically-acceptable carrier.
    Type: Application
    Filed: October 12, 2007
    Publication date: August 12, 2010
    Inventors: Stanley M. Crain, Ke-Fei Shen
  • HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS
    Publication number: 20100204220
    Abstract: Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.
    Type: Application
    Filed: July 14, 2008
    Publication date: August 12, 2010
    Inventors: Mohamed Naquib Attala, Philippe Diaz
  • DRUG FOR TREATMENT OF INFLUENZA
    Publication number: 20100204314
    Abstract: A therapeutic or prophylactic for H5N1 influenza is provided. Specifically disclosed is a therapeutic or prophylactic for H5N1 influenza comprising as an active ingredient a compound represented by the general formula (I): wherein R1 and R2 represent H or alkanoyl; X represents a halogen atom, OH, alkoxy or alkanoyloxy; and R3 represents H or alkyl; PROVIDED THAT compounds of formula (I) wherein each of R1 and R2 is H, X is OH, and R3 is H are excluded.
    Type: Application
    Filed: March 3, 2008
    Publication date: August 12, 2010
    Inventors: Makoto Yamashita, Yoshihiro Kawaoka